Zentalis Pharmaceuticals Inc (ZNTL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.99-2.92%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZNTL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | 67.4 | 0.0 | 0.0 | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 116.3 | 107.3 | 167.8 | 189.6 | 172.7 | 175.6 | 84.9 |
| Operating Income | (153.4) | (152.8) | (191.2) | (299.5) | (227.3) | (216.5) | (118.8) |
| Earnings from Continuing Operations | |||||||
| EBT, Incl. Unusual Items | — | (136.6) | (165.7) | (276.9) | (221.3) | (164.6) | (118.1) |
| Income Tax Expense | — | 0.4 | 0.2 | (0.6) | (0.5) | (0.3) | 0.4 |
| Net Income | |||||||
| Minority Interest | — | — | (0.0) | (0.1) | (0.3) | (7.4) | (0.7) |
| Net Income | (139.5) | (137.1) | (165.8) | (292.3) | (236.8) | (158.7) | (117.8) |
| Per Share | |||||||
| Basic EPS | (1.96) | (1.91) | (2.33) | (4.47) | (4.48) | (3.72) | (4.19) |
| Diluted EPS | (1.96) | (1.91) | (2.33) | (4.47) | (4.48) | (3.72) | (4.19) |
| Basic Weighted Avg Shares | 71.3 | 71.9 | 71.1 | 65.4 | 52.9 | 42.7 | 28.1 |
| Diluted Weighted Avg Shares | 71.3 | 71.9 | 71.1 | 65.4 | 52.9 | 42.7 | 28.1 |
| Supplemental | |||||||
| EBITDA | — | (152.1) | (189.9) | (298.1) | (225.9) | (216.0) | (118.6) |
| EBIT | (153.4) | (152.8) | (191.2) | (299.5) | (227.3) | (216.5) | (118.8) |
| Effective Tax Rate | — | — | — | 0.2% | 0.2% | 0.2% | -0.4% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.